The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure

American Journal of Hypertension

Volumn 24, Issue 11, 2011, Pages 1164-1180

  Laragh, John H ^a   Sealey, Jean E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

angiotensin; blood pressure; hypertension; plasma renin activity; plasma renin test; PRA; renin; salt; sodium; vasoconstriction; volume

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GUANABENZ ACETATE; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; MINOXIDIL; NADOLOL; NITROPRUSSIDE SODIUM; PRAZOSIN; RENIN; RENIN INHIBITOR; RESERPINE; SARALASIN; SODIUM; SPIRONOLACTONE; SULFONAMIDE; TERAZOSIN; UNINDEXED DRUG; VASODILATOR AGENT;

ARTICLE; BLOOD FLOW; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; DEMOGRAPHY; ESSENTIAL HYPERTENSION; EXTRACELLULAR FLUID; FUNCTION TEST; HEART BEAT; HUMAN; HYPERTENSION; JUXTAGLOMERULAR CELL; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PLASMA RENIN TEST; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; EXTRACELLULAR FLUID; HUMANS; HYPERTENSION; MODELS, CARDIOVASCULAR; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM; VASOCONSTRICTION;

EID: 80054918853     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.171     Document Type: Article

References (101)

1. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED, Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
2. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55:261-274.
3. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14:397-404. (Pubitemid 32417591)
4. Laragh JH. Laragh's Lessons in Renin System Pathophysiology for Treating Hypertension and its Fatal Cardiovascular Consequences. Elsevier Science: New York, 2002.
5. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14:491-503. (Pubitemid 32506721)
6. Dibona GF, Sawin LL. Renal tubular site of action of felodipine. J Pharmacol Exp Ther 1984; 228:420-424. (Pubitemid 14190751)
7. Yokoyama S, Kaburagi T. Clinical effects of intravenous nifedipine on renal function. J Cardiovasc Pharmacol 1983; 5:67-71. (Pubitemid 13177953)
8. Bell AJ, Lindner A. Effects of verapamil and nifedipine on renal function and hemodynamics in the dog. Ren Physiol 1984; 7:329-343. (Pubitemid 14024723)
9. Krusell LR, Jespersen LT, Christensen CK, Thomsen K, Pedersen OL. Acute natriuresis induced by inhibition of proximal tubular reabsorption of sodium and water in hypertensives following acute calcium entry blockade with nifedipine. J Cardiovasc Pharmacol 1987; 10(Suppl 10):S162-S163.
10. Tigerstedt R, Bergmann PG. Niere und kreislauf. Scand Arch Physiol 1898; 8:223-271.
11. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59:347-379.
12. Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med 1956; 44:1-15.
13. Proceeding of the International Symposium on angiotensin, sodium and hypertension. Can Med Ass J 1963; 90:151-341.
14. Ganong WF, Davis JO, Sambhi MP. Symposium on control of renin secretion. J Hypertens 1984; 2(Suppl 1):1-153.
15. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90:607-673.
16. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52:584-594.
17. Laragh JH, Ulick S, Januszewicz V, Kelly WG, Lieberman S. Electrolyte mechanism and aldosterone secretion in benign and malignant hypertension. Ann Intern Med 1960; 53:259-272.
18. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA 1960; 174:234-240.
19. Laragh JH. The role of aldosterone in man. Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. JAMA 1960; 174:293-295.
20. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003; 16:407-415. (Pubitemid 36570979)
21. Bull MB, Hillman RS, Cannon PJ, Laragh JH. Renin and aldosterone secretion in man as influenced by changes in electrolyte balance and blood volume. Circ Res 1970; 27:953-960.
22. Laragh JH, Sealey JE, Sommers SC. Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects. Circ Res 1966; 18(Suppl I):158-174.
23. Laragh JH, Sealey J, Brunner HR. The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. Am J Med 1972; 53:649-663.
24. Morganti A, Lopez-Ovejero JA, Pickering TG, Laragh JH. Role of the sympathetic nervous system in mediating the renin response to head-up tilt. Their possible synergism in defending blood pressure against postural changes during sodium deprivation. Am J Cardiol 1979; 43:600-604. (Pubitemid 9136172)
25. Brunner HR, Kirshman JD, Sealey JE, Laragh JH. Hypertension of renal origin: evidence for two different mechanisms. Science 1971; 174:1344-1346.
26. Gavras H, Brunner HB, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 1973; 180:1369-1371.
27. Gavras H, Ribeiro AB, Gavras I, Brunner HR. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med 1976; 295:1278-1283. (Pubitemid 8002877)
28. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol 1980; 239:F271-F280. (Pubitemid 10002634)
29. Assaykeen TA, Clayton PL, Goldfien A, Ganong WF. The effect of alpha-and beta-adrenergic blocking agents on the renin response to hypoglycemia and epinephrine in dogs. Endocrinology 1970; 87:1318-1322.
30. Michelakis AM, McAllister RG. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972; 34:386-394.
31. Bühler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renindependent hypertensive diseases. N Engl J Med 1972; 287:1209-1214.
32. Bühler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 1973; 32:511-522.
33. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974; 291:817-821.
34. Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 1977; 296:641-646. (Pubitemid 8060095)
35. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis 1978; 21:195-206. (Pubitemid 9068240)
36. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976; 60:825-836.
37. Timmermans PB, Carini DJ, Chiu AT, Duncia JV, Price WA Jr, Wells GJ, Wong PC, Johnson AL, Wexler RR. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991; 4: 275S-281S.
38. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22:112-121.
39. Vaughan ED Jr, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol 1973; 32:523-532.
40. Laragh JH. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med 1976; 61:797-810.
41. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
42. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
43. Blumenfeld JD, Sealey JE, Alderman MH, Cohen H, Lappin R, Catanzaro DF, Laragh JH. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens 2000; 13:855-863. (Pubitemid 30628221)
44. Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MA. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24:1181-1186.
45. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61:1461-1468. (Pubitemid 47228610)
46. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20:771-777. (Pubitemid 34913723)
47. Gavras H, Brunner HR. Letter: Renin profiling in hypertension. N Engl J Med 1976; 295:734.
48. Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80:633-644. (Pubitemid 16035581)
49. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-597. (Pubitemid 46678721)
50. Sealey JE, Parra D, Rosenstein R, Laragh JH. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55:e16; author reply e17.
51. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005; 78:501-507. (Pubitemid 41698904)
52. Sim JJ, Bhandari SK, Shi J, Kalantar-Zadeh K, Rasgon SA, Sealey JE et al. Use of antihypertensive medications in a large healthcare system: relationship to plasma renin activity (PRA) levels. Am J Hypertens, in press.
53. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12:451-459. (Pubitemid 29238406)
54. Weber MA, Case DB, Baer L, Sealey JE, Drayer JI, Lopez-Overjero JA, Laragh JH. Renin and aldosterone suppression in the antihypertensive action of clonidine. Am J Cardiol 1976; 38:825-830. (Pubitemid 8005697)
55. Safar ME, Weiss YA, Corvol PL, Menard JE, London GM, Milliez PL. Antihypertensive adrenergic-blocking agents: effects on sodium balance, the reninangiotensin system and haemodynamics. Clin Sci Mol Med Suppl 1975; 2:93s-95s.
56. Weber MA, Lopez-Ovejero JA, Drayer JI, Case DB, Laragh JH. Renin reactivity as a determinant of responsiveness to antihypertensive treatment. Arch Intern Med 1977; 137:284-289. (Pubitemid 9020956)
57. Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008; 6:305-314.
58. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111:1012-1018. (Pubitemid 40354519)
59. Ménard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R. Direct immunometric assay of active renin in human plasma. J Hypertens Suppl 1985; 3:S275-S278. (Pubitemid 17199980)
60. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37:1811-1819. (Pubitemid 121000617)
61. Morganti A. A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. J Hypertens 2010; 28: 1307-1312.
62. Summers RJ. Renal alpha adrenoceptors. Fed Proc 1984; 43:2917-2922.
63. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43:306-311. (Pubitemid 38174130)
64. Bolli P, Amann FW, Bühler FR. Antihypertensive response to post-synaptic alphablockade with prazosin in low and normal renin patients. Hypertension 1980; 2(Suppl):S399-S405. (Pubitemid 11162103)
65. Nicholson JP, Resnick LM, Laragh JH. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Arch Intern Med 1989; 149:125-128. (Pubitemid 19036828)
66. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20:771-777. (Pubitemid 34913723)
67. Nicholson JP, Resnick LM, Pickering TG, Marion R, Sullivan P, Laragh JH. Relationship of blood pressure response and the renin-angiotensin system to first-dose prazosin. Am J Med 1985; 78:241-244. (Pubitemid 15162924)
68. Sealey JE, Gerten-Banes J, Laragh JH. The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int 1972; 1:240-253.
69. Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med 1975; 5:189-202.
70. Bragat AC, Blumenfeld J, Sealey JE. Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J Hypertens 1997; 15: 459-465. (Pubitemid 27216003)
71. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921. (Pubitemid 23086643)
72. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
73. Sealey JE, Laragh JH. "Prorenin" in human plasma? Circ Res 1975; 36:10-16.
74. Atlas SA, Hesson TE, Sealey JE, Dharmgrongartama B, Laragh JH, Ruddy MC, Aurell M. Characterization of inactive renin ("prorenin") from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma. J Clin Invest 1984; 73:437-447. (Pubitemid 14194624)
75. Pitarresi TM, Rubattu S, Heinrikson R, Sealey JE. Reversible cryoactivation of recombinant human prorenin. J Biol Chem 1992; 267:11753-11759.
76. Skinner SL. Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate. Circ Res 1967; 20:391-402.
77. Brown JJ, Davies DL, Lever AF, Robertson JI, Tree M. The estimation of renin in human plasma. Biochem J 1964; 93:594-600.
78. Derkx FH, von Gool JM, Wenting GJ, Verhoeven RP, Man in 't Veld AJ, Schalekamp MA. Inactive renin in human plasma. Lancet 1976; 1:496-499.
79. Atlas SA, Sealey JE, Laragh JH, Moon C. Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure. Lancet 1977; 2:785-789. (Pubitemid 8193246)
80. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007; 20:907-916. (Pubitemid 47176356)
81. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792-801.
82. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17:1-7. (Pubitemid 38064751)
83. Trenkwalder P, James GD, Laragh JH, Sealey JE. Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am J Hypertens 1996; 9:621-627. (Pubitemid 26266599)
84. Egan BM, Weder AB, Petrin J, Hoffman RG. Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men. Relationship to salt-sensitivity status. Am J Hypertens 1991; 4:416-421.
85. Longworth DL, Drayer JI, Weber MA, Laragh JH. Divergent blood pressure responses during short-term sodium restriction in hypertension. Clin Pharmacol Ther 1980; 27:544-546. (Pubitemid 10099071)
86. Baer L, Parra-Carrilo JZ, Radichevich I, Williams GS. Detection of renovascular hypertension with angiotensin II blockade. Ann Intern Med 1977; 86:257-260. (Pubitemid 8055499)
87. Dimsdale JE, Ziegler M, Mills P, Berry C. Prediction of salt sensitivity. Am J Hypertens 1990; 3:429-435. (Pubitemid 20380190)
88. Brown JJ, Düsterdieck G, Fraser R, Lever AF, Robertson JI, Tree M, Weir RJ. Hypertension and chronic renal failure. Br Med Bull 1971; 27:128-135.
89. Alderman MH, Lamport B. Moderate sodium restriction. Do the benefits justify the hazards? Am J Hypertens 1990; 3:499-504. (Pubitemid 20380203)
90. Drayer JI, Keim HJ, Weber MA, Case DB, Laragh JH. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med 1976; 60:897-903.
91. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23:1031-1037.
92. Furberg CD. Renin test-guided drug treatment of hypertension: the need for clinical trials. Am J Hypertens 2011; 24:1158-1163.
93. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11:894-896. (Pubitemid 28351031)
94. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21:10-13.
95. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 2008; 21:61-66.
96. Blumenfeld JD. Plasma renin activity for predicting antihypertensive drug efficacy. Am J Hypertens 2008; 21:5-6.
97. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23:1014-1022.
98. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens 2010; 23:929-930.
99. Laragh JH, Sealey JE, Brunner HR. The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. Am J Med 1972; 53:649-663.
100. Weber MA, Drayer JI, Rev A, Laragh JH. Disparate patterns of aldosterone response during diuretic treatment of hypertension. Ann Intern Med 1977; 87:558-563. (Pubitemid 8223602)
101. Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, Kler L, Brown AN, Francis RJ. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9:39-44. (Pubitemid 17212750)